1. Home
  2. CSWC vs NVAX Comparison

CSWC vs NVAX Comparison

Compare CSWC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

HOLD

Current Price

$23.03

Market Cap

1.6B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$10.66

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
NVAX
Founded
1961
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
CSWC
NVAX
Price
$23.03
$10.66
Analyst Decision
Buy
Hold
Analyst Count
5
9
Target Price
★ $23.50
$11.33
AVG Volume (30 Days)
614.7K
★ 5.0M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
★ 10.89%
N/A
EPS Growth
29.25
★ 309.76
EPS
★ 0.39
N/A
Revenue
$10,835,000.00
★ $1,123,479,000.00
Revenue This Year
$17.45
N/A
Revenue Next Year
$10.26
N/A
P/E Ratio
$59.08
★ N/A
Revenue Growth
16.08
★ 64.69
52 Week Low
$19.37
$6.20
52 Week High
$25.75
$11.85

Technical Indicators

Market Signals
Indicator
CSWC
NVAX
Relative Strength Index (RSI) 31.78 64.76
Support Level $22.82 $8.42
Resistance Level $23.86 $10.85
Average True Range (ATR) 0.38 0.53
MACD -0.13 0.05
Stochastic Oscillator 12.27 76.77

Price Performance

Historical Comparison
CSWC
NVAX

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source of revenue comprises interest income and dividend income from investments made as well as management fees.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: